0001437749-22-017740.txt : 20220726 0001437749-22-017740.hdr.sgml : 20220726 20220726111129 ACCESSION NUMBER: 0001437749-22-017740 CONFORMED SUBMISSION TYPE: DEFA14A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20220726 DATE AS OF CHANGE: 20220726 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Vaxart, Inc. CENTRAL INDEX KEY: 0000072444 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 591212264 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: DEFA14A SEC ACT: 1934 Act SEC FILE NUMBER: 001-35285 FILM NUMBER: 221105489 BUSINESS ADDRESS: STREET 1: 170 HARBOR WAY, SUITE 300 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: (650) 550-3500 MAIL ADDRESS: STREET 1: 170 HARBOR WAY, SUITE 300 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 FORMER COMPANY: FORMER CONFORMED NAME: Aviragen Therapeutics, Inc. DATE OF NAME CHANGE: 20160413 FORMER COMPANY: FORMER CONFORMED NAME: Biota Pharmaceuticals, Inc. DATE OF NAME CHANGE: 20121113 FORMER COMPANY: FORMER CONFORMED NAME: NABI BIOPHARMACEUTICALS DATE OF NAME CHANGE: 20100719 DEFA14A 1 vxrt20220725_defa14a.htm FORM DEFA14A vxrt20220725_defa14a.htm

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of

the Securities and Exchange Act of 1934

 

Filed by the Registrant ☒

      

Filed by a Party other than the Registrant ☐

      

Check the appropriate box:

      

☐

Preliminary Proxy Statement

☐

Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

☐

Definitive Proxy Statement

      

☒

Definitive Additional Materials

      

☐

Soliciting Material Pursuant to § 240.14a-12

  

 

VAXART, INC.

(Name of Registrant as Specified in Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

 

Payment of Filing Fee (Check the appropriate box):

☒

No fee required

☐

Fee paid previously with preliminary materials

☐

Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

 

 

 

 

 

 
 

 

 

Video A2

 

Twitter:

Proposal 2 is supported by the two leading proxy firms, @issgovernance and @GlassLewis. Shareholders, click here to vote: https://investors.vaxart.com/shareholder-proxy-faq INSERT VIDEO

 

LinkedIn:

Proposal 2 is supported by the two leading proxy firms, ISS and Glass Lewis. Shareholders, click here to vote: https://investors.vaxart.com/shareholder-proxy-faq INSERT VIDEO

 

Video B2

 

Twitter:

We believe Proposal 2 will allow us to unlock significant value as we move forward. Shareholders, click here to vote: https://investors.vaxart.com/shareholder-proxy-faq INSERT VIDEO

 

LinkedIn:

We believe Proposal 2 will allow us to unlock significant value as we move forward. Shareholders, click here to vote: https://investors.vaxart.com/shareholder-proxy-faq INSERT VIDEO

 

Video C2

 

Twitter:

Proposal 2 will enable VXRT to thoughtfully raise capital as we progress our programs. Shareholders, click here to vote: https://investors.vaxart.com/shareholder-proxy-faq INSERT VIDEO

 

LinkedIn:

Proposal 2 will enable VXRT to thoughtfully raise capital as we progress our programs. Shareholders, click here to vote: https://investors.vaxart.com/shareholder-proxy-faq INSERT VIDEO

 

Video D2

 

Twitter:

Proposal 2 will help strengthen VXRT. To learn why, shareholders, click here: https://investors.vaxart.com/shareholder-proxy-faq INSERT VIDEO

 

LinkedIn:

Proposal 2 will help strengthen VXRT. To learn why, shareholders, click here: https://investors.vaxart.com/shareholder-proxy-faq INSERT VIDEO

 

Video E2

 

Twitter:

Passing Proposal 2 will enable VXRT to continue to use options as a tool to attract and retain talent while aligning our interests with those of you, the shareholders. Shareholders, click here to vote: https://investors.vaxart.com/shareholder-proxy-faq INSERT VIDEO

 

LinkedIn:

Passing Proposal 2 will enable Vaxart to continue to use options as a tool to attract and retain talent while aligning our interests with those of you, the shareholders. Shareholders, click here to vote: https://investors.vaxart.com/shareholder-proxy-faq INSERT VIDEO

 

Video F2

 

Twitter:

Proposal 2 will not cause an automatic 40% dilution to shareholders. This is a big misconception, and for the benefit of our shareholders, it's important to understand what this proposal does and what it doesn't do. Shareholders, click here to learn more and vote: https://investors.vaxart.com/shareholder-proxy-faq INSERT VIDEO

 

LinkedIn:

Proposal 2 will not cause an automatic 40% dilution to shareholders. This is a big misconception, and for the benefit of our shareholders, it's important to understand what this proposal does and what it doesn't do. Shareholders, click here to learn more and vote: https://investors.vaxart.com/shareholder-proxy-faq INSERT VIDEO